多参数MRI影像生物标志预测肝细胞癌微血管侵犯及复发风险
本研究回顾性纳入4家三级中心978例肝细胞癌患者,利用多期相MRI的瘤内异质性特征联合临床变量构建决策模型,预测微血管侵犯并进行术后复发风险分层。模型在训练、内部验证和外部验证队列AUC分别为0.912、0.875和0.882。外部验证中模型优于临床病理模型,C指数为0.776对0.702。
要点
- 多期相MRI瘤内异质性特征可无创预测肝癌微血管侵犯
- 决策模型对术后复发风险分层优于传统临床病理模型
- 模型在HBV状态和组织学分级亚组中表现稳定
核心结论
- 联合多期相MRI瘤内异质性特征与临床变量的决策模型对肝细胞癌微血管侵犯预测表现稳健,AUC在训练、内部验证和外部验证队列分别为0.912、0.875和0.882。
- 该决策模型在外部验证队列中优于临床病理模型用于复发风险分层,C指数为0.776对0.702,2年AUC为0.810对0.729,5年AUC为0.876对0.779。
研究设计与样本
- 回顾性研究,纳入4家三级医学中心978例肝细胞癌患者。
- 构建7个模型:4个单模态模型、2个双模态模型、1个三模态决策模型。
- 使用多期相MRI提取瘤内异质性特征和栖息地表型,参考标准为病理微血管侵犯评估和术后复发随访。
关键影像表现/征象
- 多期相MRI提取的瘤内异质性特征反映肿瘤内部亚区域组成差异,用于鉴别存在微血管侵犯的肝细胞癌。
- 通过栖息地表型联合建模可刻画肿瘤内部不同亚区域的成分构成,提供超越单一影像信号特征的鉴别信息。
诊断标准与关键数值
- 决策模型AUC在训练、内部验证和外部验证队列分别为0.912、0.875和0.882。
- 决策模型显著优于临床模型、所有单模态模型及放射-临床模型,p < 0.001。
- 外部验证队列中决策模型C指数为0.776,临床病理模型为0.702。
- 外部验证队列中决策模型2年AUC为0.810,5年AUC为0.876;临床病理模型2年AUC为0.729,5年AUC为0.779。
- 模型消融分析显示,在影像特征基础上加入临床变量以及联合栖息地表型和瘤内异质性指标均可获得增益。
临床应用与阅片要点
- 术前多期相MRI可辅助预测肝细胞癌微血管侵犯,有助于无创识别高风险患者。
- 决策模型提供的复发风险分层可辅助术后随访策略制定,其效能优于常规临床病理风险分层。
- 模型在乙型肝炎病毒阳性和不同组织学分级亚组中表现一致,提示适用范围较广。
局限性
- 研究为回顾性设计,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Microvascular invasion (MVI) is a major driver of recurrence and poor outcomes in hepatocellular carcinoma (HCC), yet biopsy-based pathologic assessment is invasive and susceptible to sampling bias and delayed availability. We aimed to develop and validate a noninvasive preoperative model integrating multiphase magnetic resonance imaging-derived habitat/intratumoral heterogeneity (ITH) features and clinical variables for MVI prediction and postoperative recurrence-risk stratification.
METHODS: We retrospectively analyzed 978 patients with HCC from four tertiary centers. Seven models were constructed: four unimodal, two bimodal, and one trimodal (Decision). Model performance was assessed using area under the curve (AUC), sensitivity, specificity, calibration, and decision curve analysis in the internal and external validation cohorts. Prognostic value for recurrence-free survival (RFS) was evaluated using the concordance index (C-index), time-dependent receiver operating characteristic analysis, and Kaplan-Meier analysis, and compared with clinicopathologic risk stratification. Subgroup analyses stratified by hepatitis B virus (HBV) status and histologic differentiation were used to assess robustness.
RESULTS: The decision model achieved AUCs of 0.912, 0.875, and 0.882 in the training, internal validation, and external validation cohorts, respectively, and significantly outperformed the clinical model, all unimodal models, and the Rad-Clinical model (p < 0.001). Model ablation analyses demonstrated incremental gains from incorporating clinical variables with imaging features and from jointly modeling subregional composition using habitat phenotyping and ITH metrics. In the external validation cohort, the model outperformed the clinicopathologic model for recurrence-risk stratification, with a higher C-index (0.776 vs. 0.702) and higher AUCs at 2 years (0.810 vs. 0.729) and 5 years (0.876 vs. 0.779). Performance was consistent across HBV- and histologic grade-based subgroups. SHapley Additive exPlanations analysis supported model interpretability.
CONCLUSION: The preoperative decision model demonstrated robust performance for MVI prediction and postoperative recurrence-risk stratification, supporting its potential role as an adjunct tool for preoperative risk assessment.
引用
- Liu, Jia, Wang, et al. Decoding Tumor Heterogeneity with Imaging Biomarkers Predicts Microvascular Invasion and Postoperative Risk Stratification in Hepatocellular Carcinoma. Acad Radiol. 2026. PMID: 42586894. doi:10.1016/j.acra.2026.07.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。